Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAIMA CHOHAN

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1073675526
CMS profile
140219
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,971.41

272 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,852.80 270
Education $118.61 2

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 6; records 151–200 of 272 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAIMA CHOHAN

NPI 1073675526 · CMS profile ID 140219

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 6; records 151–200 of 272 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073675526?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAIMA CHOHAN, NPI 1073675526, CMS profile ID 140219. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 272 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073675526?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SAIMA CHOHAN, NPI 1073675526, CMS profile ID 140219. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 272 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073675526?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SAIMA CHOHAN, NPI 1073675526, CMS profile ID 140219, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 272 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1073675526?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

272 matching records · $3,971.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 272 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 272.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $30.9606/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662990090 CMS
Celgene Corporation $10.8706/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672859870 CMS
Lilly USA, LLC $17.3705/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658142435 CMS
Lilly USA, LLC $2.1005/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658132341 CMS
UCB, Inc. $5.5105/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688328717 CMS
E.R. Squibb & Sons, L.L.C. $13.0805/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651226683 CMS
PFIZER INC. $17.0505/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672430253 CMS
Horizon Therapeutics plc $12.9905/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691349945 CMS
Lilly USA, LLC $5.9405/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658132339 CMS
Novartis Pharmaceuticals Corporation $16.2505/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659139079 CMS
Merck Sharp & Dohme Corporation $12.3405/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695859185 CMS
PFIZER INC. $0.3805/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672468823 CMS
PFIZER INC. $12.3705/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672472412 CMS
AbbVie, Inc. $14.9105/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647777137 CMS
Horizon Therapeutics plc $3.5105/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691349941 CMS
Lilly USA, LLC $4.5205/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658125503 CMS
Lilly USA, LLC $20.2805/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658139155 CMS
Lilly USA, LLC $2.4905/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658132337 CMS
Lilly USA, LLC $15.8705/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658145489 CMS
Lilly USA, LLC $4.7705/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658145491 CMS
AbbVie, Inc. $12.7305/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647777129 CMS
PFIZER INC. $14.0805/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672485483 CMS
PFIZER INC. $15.5305/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672481429 CMS
GENZYME CORPORATION $18.1305/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694050155 CMS
Lilly USA, LLC $5.0205/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658129019 CMS
Lilly USA, LLC $15.3405/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658132335 CMS
AbbVie, Inc. $20.4405/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647777021 CMS
Novartis Pharmaceuticals Corporation $7.0505/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659139095 CMS
PFIZER INC. $13.9505/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672413153 CMS
Sobi, Inc $23.6505/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698090789 CMS
Merck Sharp & Dohme Corporation $18.7605/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695859187 CMS
Amgen Inc. $23.8705/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662990129 CMS
Amgen Inc. $23.3604/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662990034 CMS
PFIZER INC. $19.6104/30/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672491151 CMS
E.R. Squibb & Sons, L.L.C. $14.8204/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651226681 CMS
Janssen Biotech, Inc. $12.0204/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658371123 CMS
Horizon Therapeutics plc $12.7204/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691349939 CMS
PFIZER INC. $13.7004/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672477907 CMS
Amgen Inc. $1.2104/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662990029 CMS
Amgen Inc. $7.0904/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662990125 CMS
Genentech USA, Inc. $1.6304/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681160644 CMS
GENZYME CORPORATION $20.7704/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694004107 CMS
Amgen Inc. $18.6504/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662990087 CMS
Amgen Inc. $5.2004/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662990023 CMS
Horizon Therapeutics plc $5.8404/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691349937 CMS
Lilly USA, LLC $2.4904/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658135797 CMS
Lilly USA, LLC $21.5504/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658139153 CMS
PFIZER INC. $8.8404/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672465539 CMS
GENZYME CORPORATION $18.4104/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694036085 CMS
PFIZER INC. $12.6004/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672430147 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,971.41 272
PY2020 $3,378.94 134
PY2021 $2,499.15 139
PY2022 $3,192.99 153
PY2023 $3,408.39 164
PY2024 $3,018.94 145
PY2025 $2,515.30 126

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $931,082.46 54
PY2024 Principal investigator $339,887.91 85
PY2023 Principal investigator $137,565.67 36
PY2022 Principal investigator $85,206.39 63
PY2021 Principal investigator $150,189.20 89
PY2020 Principal investigator $130,022.48 52
PY2019 Principal investigator $137,479.44 46

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,080.70 12/01/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289140
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,080.70 11/19/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288595
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,962.80 11/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430758
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $55.90 10/27/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430700
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 10/24/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223287645
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,395.80 10/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286349
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,040.00 10/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286351
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,517.23 10/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430722
Principal investigator 1 Amgen Inc. $8,770.95 08/25/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - GLENDALE - 5681 W BEVERLY LN
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246639205
Principal investigator 1 Amgen Inc. $31,771.45 07/16/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246639269
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $325.00 07/14/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430764
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,788.20 07/11/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430744
Principal investigator 1 ARGENX US, INC. $1,544.40 07/09/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis No dispute reported 06/30/2026 1237146602
Principal investigator 1 Amgen Inc. $114,294.79 07/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639293
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $677.30 07/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430710
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,998.02 06/25/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430680
Principal investigator 1 ARGENX US, INC. $4,861.50 06/18/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis No dispute reported 06/30/2026 1237146598
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,467.45 06/11/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430730
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $209.30 06/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430702
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,000.00 05/22/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab. No dispute reported 06/30/2026 1246430814
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $120.00 05/21/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430686
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $495.14 05/12/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430800
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,200.00 05/08/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab. No dispute reported 06/30/2026 1246430810
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $623.10 05/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430738
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $315.93 05/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430796
Principal investigator 1 Amgen Inc. $23,567.99 05/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1246639231
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $500.00 04/23/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430770
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $400.40 04/22/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab. No dispute reported 06/30/2026 1246430812
Principal investigator 1 Amgen Inc. $450.00 04/18/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1246639257
Principal investigator 1 Amgen Inc. $9,654.88 04/08/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS CLINIC - CHANDLER
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639333
Principal investigator 1 Amgen Inc. $71,686.05 04/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639247
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $140.40 04/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430774
Principal investigator 1 Amgen Inc. $22,662.45 03/19/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - GLENDALE - 5681 W BEVERLY LN
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity No dispute reported 06/30/2026 1246639211
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,273.10 03/17/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430752
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $15,947.10 03/14/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430684
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,321.35 03/10/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430694
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,119.74 03/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430794
Principal investigator 1 AstraZeneca UK Limited $6,265.02 03/05/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOL
A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus No dispute reported 06/30/2026 1185545029
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $373.10 03/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430728
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,105.00 02/26/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223275681
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,101.00 02/22/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430788
Principal investigator 1 Amgen Inc. $11,931.00 02/21/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - MESA - 2152 S VINEYARD
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1246639221
Principal investigator 1 ARGENX US, INC. $17,900.00 02/14/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis No dispute reported 06/30/2026 1237146381
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $316.05 02/12/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430786
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $13,787.80 02/05/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430716
Principal investigator 1 Amgen Inc. $22,830.00 02/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1246639303
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $674.70 02/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430768
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $269.40 01/28/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430784
Principal investigator 1 Amgen Inc. $10,881.00 01/17/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - GLENDALE - 5681 W BEVERLY LN
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants with Sjgrens Syndrome With Moderate-to-Severe Symptom State No dispute reported 06/30/2026 1246639209
Principal investigator 1 Amgen Inc. $9,340.99 01/17/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1246639261
Principal investigator 1 Amgen Inc. $21,820.14 01/08/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - GLENDALE - 5681 W BEVERLY LN
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639213
Principal investigator 1 AstraZeneca UK Limited $19,871.50 01/08/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus No dispute reported 06/30/2026 1185545031
Principal investigator 1 Amgen Inc. $363,151.68 01/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS CLINIC - CHANDLER
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246639337
Principal investigator 1 Amgen Inc. $60,044.96 01/02/2025 Non-covered Recipient Entity
ARIZONA RESEARCH CLINIC PLLC
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246639347